I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

Retina Society 2023

-
Coming soon
02:47 PM
Duration 4mins InterContinental New York Barclay - Grand Ballroom
Clinical Outcomes of Diabetic Macular Edema Patients Treated with Faricimab▼ and Aflibercept: A Subcohort Analysis of 20/50 or Worse Visual Acuity Across Faricimab▼ Phase 3 Clinical Trials
Holekamp N, Zarbin M, Ding A, Lu X, Ahmed A, Yang M, Evolo V, Stoilov I, Amador M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:53 PM
Duration 5mins InterContinental New York Barclay - Grand Ballroom
Faricimab▼ Treat-and-Extend–based Dosing Dynamics in the Phase 3 YOSEMITE/RHINE Trials
Yonekawa Y, Figueroa M, Pearce I, Lim J, Gibson K, Jain N, Shildkrot E, Souverain A, Yang M, Willis J, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:58 PM
Duration 3mins InterContinental New York Barclay - Grand Ballroom
Time to Retinal Fluid Control With Faricimab▼ vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Finn A, Walter S, Lanzetta P, Rachitskaya A, Camino A, Gibson K, Mar F, Shildkrot E, Tang Y, Willis J, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:01 PM
Duration 5mins InterContinental New York Barclay - Grand Ballroom
Faricimab▼ Reduces Macular Leakage vs Aflibercept in Patients With Diabetic Macular Edema
Eichenbaum D, Sivaprasad S, Kolomeyer A, Nudleman E, Csaky K, Willis J, Gibson K, Wang T, Haskova Z, Shildkrot E, Amador M, Mar F, Goldberg R, Camino A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:18 PM
Duration 5mins InterContinental New York Barclay - Grand Ballroom
Efficacy and Safety of Faricimab▼ in ALTIMETER: A Trial Exploring Biomarkers of Ang-2 Inhibition in Patients With DME
Fawzi A, Mar F, Amador M, Glittenberg C, Gibson K, Kotak A, Souverain A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:25 PM
Duration 5mins InterContinental New York Barclay - Grand Ballroom
Early Treatment Patterns and Outcomes in DME Patients Initiating Faricimab▼ in the US and UK
Borkar D, Tabano D, Garmo V, Leng T, Myers R, Laprise A, Singh R, Talks J, Peto T, Dayal P,

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:09 AM
Duration 5mins InterContinental New York Barclay - Grand Ballroom
Individualised faricimab▼ dosing increased the proportion of patients with nAMD on Q16W dosing in year 2 of TENAYA/LUCERNE, while maintaining functional and anatomical outcomes
Engelbert M, Sorenson J, Ambresin A, Kotecha A, Willis J, Souverain A, Shildkrot E, Swaminathan B, Margaron P, Chaudhary V

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:16 AM
Duration 4mins InterContinental New York Barclay - Grand Ballroom
Predictors of Outcomes at Year 1 in Patients Treated With Faricimab in TENAYA/LUCERNE
Kim J, Stoilov I, Yang M, Hill L

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:23 AM
Duration 6mins InterContinental New York Barclay - Grand Ballroom
Greater Reduction in Pigment Epithelial Detachment Size With Faricimab▼ vs Aflibercept During Head-to-Head Dosing in Patients With nAMD
Lim J, Margaron P, Souverain A, Yang M, Shildkrot E, Kotecha A, Willis J, Patel S, Khanani A, Bakri S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
08:35 AM
Duration 3mins InterContinental New York Barclay - Grand Ballroom
Early Treatment Patterns and Outcomes in nAMD Patients Initiating Faricimab▼ in the US and UK
Leng T, Tabano D, Garmo V, Borkar D, Myers R, Laprise A, Singh R, Talks J, Peto T, Dayal P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:49 AM
Duration 7mins InterContinental New York Barclay - Grand Ballroom
Port Delivery System With Ranibizumab (PDS) in Diabetic Macular Edema (DME): Primary Analysis Results of the Phase 3 Pagoda Trial
Klufas M, Marcus D, Graff J, Campochiaro P, Rahman S, Malhotra V, Latkany P, Gune S, DeGraaf S, Cavichini-Cordeiro M, Bobbala A, Rabena M, Quezada-Ruiz C, Khanani A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
10:56 AM
Duration 7mins InterContinental New York Barclay - Grand Ballroom
Port Delivery System With Ranibizumab (PDS) in Patients With Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME): Primary Analysis Results of the Phase 3 Pavilion Trial
Regillo C, Wykoff C, Chang M, Emanuelli A, Holekamp N, Latkany P, Malhotra V, Brittain C, Howard D, Cavichini-Cordeiro M, Santhanakrishnan A, Wetzel-Smith M,

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:09 AM
Duration 4mins InterContinental New York Barclay - Grand Ballroom
Pharmacokinetic (PK) Profile of the Port Delivery System With Ranibizumab (PDS) in the Phase 3 Pagoda and Pavilion Trials
Wolfe J, Dhoot D, Ding HT, Hyung S, Latkany P, Maass K, Rahman S, Hsu J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:30 PM
Duration 3mins InterContinental New York Barclay - Grand Ballroom
Regional Variance in the Enrollment of Underrepresented Patients in US Clinical Trials of DME
Khan MA, Blotner S, Hill L, Amador M, Haller J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar